ATE527378T1 - Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression - Google Patents

Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression

Info

Publication number
ATE527378T1
ATE527378T1 AT04781089T AT04781089T ATE527378T1 AT E527378 T1 ATE527378 T1 AT E527378T1 AT 04781089 T AT04781089 T AT 04781089T AT 04781089 T AT04781089 T AT 04781089T AT E527378 T1 ATE527378 T1 AT E527378T1
Authority
AT
Austria
Prior art keywords
mitogen
protein kinase
activated protein
kinase expression
antisense modulation
Prior art date
Application number
AT04781089T
Other languages
English (en)
Inventor
Brett P Monia
Kenneth W Dobie
Susan M Freier
Ian Popoff
Wai Shiu Fred Wong
James G Karras
Original Assignee
Isis Pharmaceuticals Inc
Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc, Univ Singapore filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE527378T1 publication Critical patent/ATE527378T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11024—Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
AT04781089T 2003-08-15 2004-08-12 Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression ATE527378T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/641,455 US20040171566A1 (en) 1999-04-06 2003-08-15 Antisense modulation of p38 mitogen activated protein kinase expression
PCT/US2004/026344 WO2005016947A2 (en) 2003-08-15 2004-08-12 ANTISENSE MODULATION OF p38 MITOGEN ACTIVATED PROTEIN KINASE EXPRESSION

Publications (1)

Publication Number Publication Date
ATE527378T1 true ATE527378T1 (de) 2011-10-15

Family

ID=34193611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04781089T ATE527378T1 (de) 2003-08-15 2004-08-12 Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression

Country Status (4)

Country Link
US (2) US20040171566A1 (de)
EP (1) EP1660682B1 (de)
AT (1) ATE527378T1 (de)
WO (1) WO2005016947A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171566A1 (en) * 1999-04-06 2004-09-02 Monia Brett P. Antisense modulation of p38 mitogen activated protein kinase expression
US7407943B2 (en) * 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
US20040115634A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
EP2316941A3 (de) 2005-02-25 2012-03-14 Isis Pharmaceuticals, Inc. Auf IL-4R gerichtete Zusammensetzungen und deren Verwendungen
US7585968B2 (en) 2005-03-28 2009-09-08 Isis Pharmaceuticals, Inc. Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
US20060258610A1 (en) 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
US20070270366A1 (en) * 2005-12-20 2007-11-22 Karras James G Double stranded nucleic acid molecules targeted to il-4 receptor alpha
WO2007134014A2 (en) 2006-05-05 2007-11-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of gcgr
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
KR20150090284A (ko) * 2007-03-24 2015-08-05 젠자임 코포레이션 인간 아포리포프로틴 ｂ에 상보적인 안티센스 올리고뉴클레오타이드 투여
BRPI0817605A2 (pt) 2007-10-03 2017-05-09 Quark Pharmaceuticals Inc novas estruturas de sirna
US8341614B2 (en) * 2008-06-06 2012-12-25 Apple Inc. Memory management for closures
EP2408796B1 (de) 2009-03-16 2020-04-22 Ionis Pharmaceuticals, Inc. Targeting Apolipoprotein B für die Reduktion von Apolipoprotein C-III
WO2010120511A2 (en) 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Method of treating respiratory disorders
US8648053B2 (en) 2010-10-20 2014-02-11 Rosalind Franklin University Of Medicine And Science Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
US9353371B2 (en) * 2011-05-02 2016-05-31 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with usher syndrome
US8981318B1 (en) 2011-12-30 2015-03-17 Gene Capture, Inc. Multi-dimensional scanner for nano-second time scale signal detection
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US10729690B2 (en) 2016-01-13 2020-08-04 University Of Massachusetts Antihelminthic medications for pathogenic nematodes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519016A1 (de) 1990-03-07 1992-12-23 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verfahren zur diagnose der lyme-krankheit
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5872242A (en) * 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
WO1997004104A2 (en) 1995-07-14 1997-02-06 The Johns Hopkins University Tumor type ii hexokinase transcription regulatory regions
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US20030228597A1 (en) * 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
EP1080225A4 (de) 1998-05-21 2004-02-04 Isis Pharmaceuticals Inc Zusammensetzungen und methoden zur pulmonalen verabreichung von nukleinsäuren
US6140124A (en) * 1999-04-06 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of P38 mitogen activated protein kinase expression
US20040171566A1 (en) 1999-04-06 2004-09-02 Monia Brett P. Antisense modulation of p38 mitogen activated protein kinase expression
US6906186B1 (en) * 2002-07-30 2005-06-14 Isis Pharmaceuticals, Inc. Antisense modulation of polo-like kinase expression

Also Published As

Publication number Publication date
WO2005016947A3 (en) 2006-01-05
EP1660682B1 (de) 2011-10-05
US20080194503A1 (en) 2008-08-14
US7981868B2 (en) 2011-07-19
EP1660682A4 (de) 2007-03-07
EP1660682A2 (de) 2006-05-31
WO2005016947A2 (en) 2005-02-24
US20040171566A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
ATE527378T1 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
EA200600591A1 (ru) МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
ATE286118T1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
ATE531383T1 (de) Therapeutische verwendung eines wachstumsfaktors, metrnl
ATE517996T1 (de) Verfahren und mittel zur erhöhung der toleranz von pflanzen gegenüber stressbedingungen
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
ATE481978T1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
AR025683A1 (es) Composiciones de d-endotoxina de bacillus thuringiensis activas contra lepidopteros y metodos de uso
CY1110885T1 (el) Πεπτιδια που μπορουν να συνδεθουν στον αυξητικο παραγοντα μεταμορφωσης βητα 1 (tgf-beta1)
WO2004063362A3 (en) Cell cycle progression proteins
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
WO2004019893A3 (en) Modulators of angiogenesis
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
ATE527377T1 (de) Erstellung von genexpressionprofilen aus ffpe- proben
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
ATE501252T1 (de) Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
DE50009365D1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
DE60327068D1 (de) Verwendung von xenon zur kontrolle von neurologischen defiziten im zusammenhang mit kardiopulmonalem bypass
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties